A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain
Purpose of Review: Chronic pain continues to be one of the leading healthcare cost burdens in the United States and is typically defined as ongoing pain, lasting longer than six months. Various treatment options exist for chronic pain, including physical therapy, medical management, pain psychology, and interventional therapies. Pain medications have been the mainstay of treatment for chronic pain conditions with an increasing use of membrane stabilizers and antidepressants to treat neuropathic pain conditions. Specifically, serotonin noradrenaline reuptake inhibitors (SNRIs) have been used to treat a range of pain conditions expanding from everyday use for depressive disorders.
Recent Findings: SNRIs, including duloxetine, venlafaxine, and milnacipran, have demonstrated efficacy in reducing pain in musculoskeletal pain (chronic low back pain and osteoarthritis), fibromyalgia, and neuropathic pain conditions (peripheral diabetic neuropathy).
Summary: The article describes the function, role, and use of SNRIs to treat chronic and neuropathic pain by altering the noradrenergic descending inhibitory pathways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Health psychology research - 10(2022), 3 vom: 30., Seite 32309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Robinson, Christopher [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic pain |
|---|
| Anmerkungen: |
Date Revised 22.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.52965/001c.32309 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342957368 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342957368 | ||
| 003 | DE-627 | ||
| 005 | 20231226015314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.52965/001c.32309 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM342957368 | ||
| 035 | |a (NLM)35774919 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Robinson, Christopher |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Purpose of Review: Chronic pain continues to be one of the leading healthcare cost burdens in the United States and is typically defined as ongoing pain, lasting longer than six months. Various treatment options exist for chronic pain, including physical therapy, medical management, pain psychology, and interventional therapies. Pain medications have been the mainstay of treatment for chronic pain conditions with an increasing use of membrane stabilizers and antidepressants to treat neuropathic pain conditions. Specifically, serotonin noradrenaline reuptake inhibitors (SNRIs) have been used to treat a range of pain conditions expanding from everyday use for depressive disorders | ||
| 520 | |a Recent Findings: SNRIs, including duloxetine, venlafaxine, and milnacipran, have demonstrated efficacy in reducing pain in musculoskeletal pain (chronic low back pain and osteoarthritis), fibromyalgia, and neuropathic pain conditions (peripheral diabetic neuropathy) | ||
| 520 | |a Summary: The article describes the function, role, and use of SNRIs to treat chronic and neuropathic pain by altering the noradrenergic descending inhibitory pathways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Serotonin noradrenaline reuptake inhibitors | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a duloxetine | |
| 650 | 4 | |a milnacipran | |
| 650 | 4 | |a neuropathic pain | |
| 650 | 4 | |a venlafaxine | |
| 700 | 1 | |a Dalal, Suhani |e verfasserin |4 aut | |
| 700 | 1 | |a Chitneni, Ahish |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Amnon A |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmood, Syed |e verfasserin |4 aut | |
| 700 | 1 | |a Orhurhu, Vwaire |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Hasoon, Jamal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health psychology research |d 2013 |g 10(2022), 3 vom: 30., Seite 32309 |w (DE-627)NLM243870574 |x 2420-8124 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:3 |g day:30 |g pages:32309 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.52965/001c.32309 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 3 |b 30 |h 32309 | ||